They found that shortly after treatment, some cancer cells enter a quiescent state with low KRAS activity, while others bypass inhibition by producing newly synthesised KRASG12C, which is maintained in an active, drug‐insensitive state via EGFR‐ and AURKA‐driven signalling. The gene discussed is EGFR; the disease is cancer.